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Abstract 
The white dot syndromes (WDS) are a diverse group of posterior uveitidies that share similar clinical findings but are 
unique from one another. Multimodal imaging has allowed us to better understand the morphology, the activity and 
age of lesions, and whether there is CNV associated with these different ocular pathologies. The “white dot syndromes” 
and their uveitic masqueraders can now be anatomically categorized based on lesion localization. The categories 
include local uveitic syndromes with choroidal pathology, systemic uveitic syndromes with choroidal pathology, and 
multifocal choroiditis with outer retinal/choriocapillaris pathology with uveitis and without uveitis. Neoplastic and 
infectious etiologies are also discussed given their ability to masquerade as WDS.
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Background
The white dot syndromes (WDS) are a group of inflam-
matory disorders that affect the outer retinal layers, reti-
nal pigment epithelium (RPE), and/or choroid [1]. WDS 
include: birdshot chorioretinopathy (BCR), multiple eva-
nescent white dot syndrome (MEWDS), acute posterior 
multifocal placoid pigment epitheliopathy (APMPPE), 
multifocal choroiditis with panuveitis (MCP), serpigi-
nous choroiditis (SC), punctate inner choroidopathy/
multifocal choroiditis (PIC/MFC), and relentless placoid 
chorioretinitis (RPC). Although overlap and spectrums 
exist among these diseases, expanded imaging tech-
niques in recent years have further clarified that each 
WDS represents a unique entity. More precise anatomic 
localization of the lesions has become possible with com-
bined imaging modalities using spectral-domain optical 
coherence tomography (SD-OCT), enhanced depth SD-
OCT imaging, fluorescein angiography (FA), indocyanine 
green angiography (ICGA), ultrasonography, wife-field 
imaging, and autofluorescence. In addition, OCT Angi-
ography is a new modality that has been proven useful 
in the diagnosis of choroidal neovascularization (CNV). 
Therefore, anatomic classification of these diseases may 
be more appropriate in the current era, rather than lump-
ing them as “white dot syndromes” (Table 1).
Treatment is not a focus of this review paper but it 
should be noted that in all of the following syndromes 
that anterior inflammation should be controlled with 
topical steroids and cycloplegics. Management of poste-
rior sequelae is noted below where pertinent.
Main text
Uveitic syndromes with choroidal‑based pathology
Sympathetic ophthalmia
Sympathetic ophthalmia (SO) is a bilateral granuloma-
tous uveitis that occurs weeks to several decades fol-
lowing a penetrating injury or surgical trauma to an eye. 
Typically, the inflammatory process is confined to the 
choroid [2–4]. Early on, bilateral anterior cell and mut-
ton-fat keratic precipitates can be observed. Thickening 
of the iris secondary to infiltration of inflammatory cells 
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and posterior synechiae may also be seen. Posterior-seg-
ment examination may reveal vitritis, an exudative reti-
nal detachment, and optic disc edema. The classic fundus 
finding is the presence of Dalen-Fuchs nodules which 
appear as focal, elevated yellowish-white lesions between 
the retinal pigment epithelium (RPE) and Bruch’s mem-
brane [2, 3]. With disease progression, patients develop a 
“sunset glow fundus” secondary to depigmentation of the 
choroid.
Ultrasound reveals choroidal thickening and may dis-
close an exudative retinal detachment. Diffuse choroidal 
thickening, subretinal fluid, and irregular inner and outer 
segment (IS/OS) junction and external limiting mem-
brane bands can be seen on SD-OCT [5, 6]. Fluorescein 
angiography demonstrates disk leakage and numerous 
progressively hyperfluorescent dots at the level of the 
RPE corresponding to pinpoint leakage. Occasionally, 
early focal blockage of the background choroidal fluores-
cence is seen [7]. Choroidal granulomas can be appreci-
ated on ICGA as numerous hypocyanescent patches in 
the intermediate phase that may progress to isocyanes-
cent in the late phase [8–10].
The prognosis for patients with SO dramatically 
improves with the use of corticosteroids and/or immuno-
suppressive agents [11, 12]. It is essential that treatment 
be initiated early in the course of the disease in order to 
prevent significant vision loss.
Systemic uveitic syndromes with choroidal‑based 
pathology
Vogt–Koyanagi–Harada disease
Vogt–Koyanagi–Harada (VKH) is a bilateral granuloma-
tous uveitis. It is often associated with an exudative reti-
nal detachment and extraocular manifestations, such as 
pleocytosis of cerebrospinal fluid, tinnitus, hearing loss, 
dysacusis, and cutaneous changes (e.g.: alopecia, polio-
sis, and vitiligo). It has a predilection for pigmented races 
such as Asians, Hispanics, American Indians, and Asian 
Indians [13, 14].
Patients may initially complain of a non-specific viral-
like illness, including fever, nausea, headaches, dizziness, 
orbital pain, photophobia and meningism. Following 
this prodromal stage, patients will experience bilateral 
blurring of vision secondary to posterior uveitis. As the 
disease progresses the inflammation extends into the 
anterior segment leading to anterior chamber cell and 
flare including mutton-fat keratic precipitates. A few 
months after this uveitic phase, choroidal depigmenta-
tion leading to a sunset glow fundus is seen. Chorioreti-
nal atrophy may also be apparent, with a predilection for 
the inferior mid-periphery of the fundus.
Imaging studies are vital to diagnose and monitor the 
disease (Fig. 1). Ultrasound may reveal a shallow ante-
rior chamber, cilio-choroidal detachment, thickened 
ciliary body, and serous retinal detachment. Enhanced 
depth imaging (EDI) OCT reveals a thickened cho-
roid and can be used to monitor serous retinal detach-
ments. Hypofluorescent pinpoint dots at the early 
phase of FA followed by multiple focal areas of leak-
age and subretinal dye accumulation at the late phase 
can be seen [15–17]. In chronic VKH, peripheral FAF 
abnormalities are seen. ICGA reveals early choroidal 
stromal vessel hypercyanescence and vascular leakage, 
and hypocyanescent dark dots at the level of the cho-
roid in the late phase. Disc hyperfluorescence may also 
be seen [18, 19].
Treatment involves an extended course of corticoster-
oids, often greater than 6 months. The addition of immu-
nomodulatory therapy should be utilized in uncontrolled 
cases. Better visual outcomes have been seen in cases 
with earlier treatment [20].
Sarcoidosis
Sarcoidosis is a granulomatous disorder of unknown eti-
ology. The disease is multi-systemic with ocular involve-
ment being found in 15–30% of sarcoid patients [21–25]. 
Although the disease can affect all races and genders, it is 
most frequently seen in African Americans [25].
Table 1 Updated classification system
Uveitic syndromes with choroidal-based pathology
 Sympathetic ophthalmia
Systemic uveitic syndromes with choroidal-based pathology
 Vogt–Koyanagi–Harada disease
 Sarcoidosis
Multifocal choroiditis with outer retinal/choriocapillaris-based pathology
 Without vitritis
  Histoplasmosis
  Punctate inner choroidopathy
 With vitritis
  Multifocal choroiditis with panuveitis
  Multiple evanescent white dot syndrome
  Acute posterior multifocal placoid pigment epitheliopathy
  Serpiginous choroiditis
  Relentless placoid chorioretinitis
  Birdshot chorioretinopathy
Neoplastic
 Primary uveal lymphoma
 Primary vitreoretinal lymphoma
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Sarcoidosis can affect the orbit, adnexa, anterior and/
or posterior segment. Anterior segment findings may 
include anterior uveitis with stereotypical mutton-fat 
keratic precipitates, iris nodules, conjunctival nodules 
and scleral nodules. Up to 60% of patients with ocular 
disease have posterior segment findings including vitritis, 
chorioretinitis, vascular occlusion, perivascular sheath-
ing, neovascularization, and optic nerve head granulo-
mas. Vitreous inflammation may clump to form “string 
of pearls” or “snowball” vitreous opacities. Periphlebi-
tis is commonly found in the peripheral or mid-periph-
eral retina with severe periphlebitis being described as 
appearing as “candle-wax drippings.” Choroidal granu-
lomas appear as isolated or multifocal elevated, subreti-
nal, round-shaped, yellowish lesions. Large granulomas 
can have overlying serous retinal detachments. On EDI-
OCT, Choroidal granulomas appeared as hyporeflective 
thickening of the choroid [26–28]. On FA, the lesions 
can demonstrate hypofluorescence, isofluorescence, early 
blocking with late staining, and hyperfluorescence [26, 
29, 30]. Many reports have described the choroidal gran-
ulomas as hypofluorescent on ICGA [28, 31].
Treatment includes topical corticosteroid drops for 
anterior chamber inflammation and cystoid macular 
edema (CME). However, inflammation of the posterior 
segment typically involves the use of sub-Tenon’s cor-
ticosteroid injections, intravitreal triamcinolone ace-
tonide, corticosteroid implant, or immunomodulatory 
therapy. Cycloplegic eye drops can be given to relieve 
ciliary spasm and to prevent the formation of posterior 
synechiae [25].
Multifocal choroiditis with outer retinal/
choriocapillaris‑based pathology without vitritis
Ocular histoplasmosis syndrome
Ocular histoplasmosis syndrome (OHS) is a chorioretinal 
disorder due to an infection from Histoplasmosis cap-
sulatum, a dimorphic fungus that is endemic to Missis-
sippi and Ohio River valleys in the United States [32, 33]. 
Humans inhale infectious spores or conidia that subse-
quently disseminate into the bloodstream and eventually 
subside. After initial exposure to the fungus, patients may 
develop mild flu-like symptoms and asymptomatic calci-
fied pulmonary nodules. Patients typically complain of 
Fig. 1 Sunset glow fundus in Vogt–Koyanagi–Harada (VKH) disease. Progressive choroidal depigmentation occurs after chronic VKH. Note the peri-
papillary depigmentation that gives the fundus a red appearance (a–b). Fundus autofluorescence shows patchy hyperautofluorescence (c–d)
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visual symptoms including vision loss, metamorphopsia, 
and paracentral scotomata years following the resolution 
of the systemic infection when choroidal neovasculariza-
tion (CNV) develops [34].
Ophthalmoscopy reveals an absence of vitritis or ante-
rior segment inflammation. Posterior segment exami-
nation uncovers the classic triad of “punched-out” 
chorioretinal lesions in the mid-periphery and posterior 
pole (“histo spots”), chorioretinal peripapillary atrophy 
(PPA) and CNV. A general consensus is that at least two 
of the three posterior segment findings must be present 
in order to make the diagnosis of OHS. In the acute phase 
of disease, the histo spots will appear creamy-white and 
become slightly larger in size and more pigmented as the 
disease progresses. On OCT, in areas of affected outer 
retina (histo spots), there is loss of the intrinsic reflec-
tance leading to the appearance of disorganization of 
the normal hyper-reflective bands [34]. In asymptomatic 
patients, FA findings show an early window defect pattern 
of hyperfluorescence with late progressive staining of the 
mid-peripheral atrophic spots and atrophic macular scars. 
If subretinal fluid or subretinal hemorrhage is present, 
early hyperfluorescence and late leakage from small blood 
vessels in the subretinal or subretinal pigment epithe-
lial space is diagnostic of CNV. CNV can also be seen on 
OCT angiography (OCT-A). On fundus autofluorescence 
(FAF), OHS lesions correspond to areas of round hypo-
autofluorescence. ICGA may be helpful in evaluation of 
occult CNV exhibiting early increased hypercyanescence 
corresponding to new, disorganized choriocapillaris.
Punctate inner choroidopathy
Punctate inner choroidopathy (PIC) tends to occur in 
Caucasian, young, myopic female (90%) patients. Patients 
complain of photopsias, blurred vision, paracentral sco-
tomas, and metamorphopsia. Fundoscopic examination 
during the acute phase of disease shows discrete, small 
(100-300  μm), well-delineated, yellow-white lesions in 
the posterior pole at the level of the RPE, inner choroid 
or the choriocapillaris (Fig. 2) [35–37]. These lesions may 
coalesce and develop a serous retinal detachment. Addi-
tionally, they may gradually atrophy and become yellow-
white chorioretinal scars, which may become pigmented 
over time. Mild optic disc edema can also be present. 
CNV is seen on initial presentation in 40–76% of patients 
[36, 38–40]. Examination does not show signs of anterior 
uveitis or vitritis [38].
OCT may reveal focal elevation of the RPE with under-
lying hyporeflective space and focal atrophy of the outer 
retina and RPE. Intraretinal fluid will be seen on OCT if 
CNV is present [41]. OCT angiography will detect CNV. 
The choroidal morphology seen on OCT includes pres-
ence of focal hyperreflective dots in the inner choroid 
and focal thinning of the choroid adjacent to PIC lesions 
[37, 42]. FA reveals more lesions than seen on clinical 
exam that appear as early hyperfluorescent lesions, and 
stain late. Atrophic lesions appear as window defects [1]. 
Leakage of fluorescence may be seen in the subretinal 
space if a serous detachment is present and late stain-
ing if CNV is present [36]. FAF shows active lesions as 
hypoautofluorescent spots with a hyperautofluorescent 
margin [43]. On ICGA, the lesions will appear hypocy-
anescent and will equal to the number seen on FA. No 
changes in electroretinography (ERG) or electrooculo-
gram (EOG) are present.
CNV and CME can cause significantly impaired vision 
over time. Aggressive treatment of CNV can be associ-
ated with the maintenance of 20/40 or better visual acuity 
[44]. Recurrence is common and can be seen in 33–66.7% 
of patients [44–46].
Multifocal choroiditis with outer retinal/
choriocapillaris‑based pathology with vitritis
Multifocal choroiditis with Panuveitis
Multifocal choroiditis with panuveitis (MCP) is a 
chronic, bilateral disease that generally affects young, 
healthy individuals, especially myopic females between 
the third and fifth decade of life [47, 48]. Patients com-
plain of blurred vision, floaters and/or scotoma. They 
may also experience photopsias. The choroid, RPE, and 
retina are primarily involved [49].
Patients develop periodic episodes of clinically evident 
anterior uveitis and/or vitreous inflammation, differenti-
ating it from ocular histoplasmosis. Yellow-white chori-
oretinal inflammatory lesions are visible in the posterior 
pole and periphery [50]. The lesions eventually evolve 
into punched-out scars with pigmented borders. Both 
eyes are generally affected, however, lesions may appear 
asymmetric due to delayed development between the two 
eyes. During active disease, a hyperemic disc, retinal vas-
culitis and CME can also be seen [51]. The most frequent 
cause of severe visual loss in these patients is from the 
development of CME and/or macular and juxtapapillary 
CNV [39, 52].
OCT reveals the presence of drusen-like sub-RPE 
material, choroidal hyperreflectivity below the lesions, 
and overlying vitreous cells [53]. On FA, acute lesions 
exhibit early hypofluoresence with late hyperfluorescent 
staining. CME and CNV may also be seen. FAF reveals 
hypoautofluorescent lesions in the posterior pole and 
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Fig. 2 Punctate inner choroidopathy (PIC). A 43-year-old myopic woman presented with bilateral multifocal lesions (a–b). Fluorescein angiography 
(FA) showed blockage and mild rims of hyperfluorescence in earlier frames (c, e), which stained over time (g, i). Indocyanine green (ICG) showed 
similar patterns but more hypocyanescent overall (d, h, f, j). Fundus autofluorescence demonstrated hypoautofluorescence of the lesions seen on 
FA and ICG (k, m). Infrared imaging showed hyperreflectance of the lesions (o, q). Spectral-domain optical coherence tomography through the 
fovea of the right eye was normal (l), but the B-scans through the lesion superior to the fovea revealed disruption of the outer retina and retinal pig-
ment epithelium (p). Similar lesions were noted in the left eye (n, r)
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periphery. ICGA imaging shows hypocyanescent spots 
within the choroid in quantities greater than lesions seen 
on ophthalmoscopy. Multifocal ERG generally reveals 
diffuse loss of function [54]. A recent study has shown 
the utility of OCT-angiography in diagnosis and evaluat-
ing response to treatment of associated CNV [55].
Disease reoccurrence is common [56]. Many patients 
with MCP have a poor visual prognosis due to disci-
form macular scarring, atrophy, or chronic CME [49, 50]. 
Treatment relies on the use of topical or periocular cor-
ticosteroids with use of systemic immunosuppressives if 
warranted. Secondary CNV can be managed expectantly 
with anti-VEGF agents.
Multiple evanescent white dot syndrome
MEWDS is an acute, multifocal, mostly unilateral dis-
ease affecting young adults. It affects females more than 
males with a ratio of 5:1 [57]. These patients are typi-
cally healthy and in their second to fourth decades of life. 
Roughly one half of the patients affected by this disease 
state that they had a prodromal flu-like illness preceding 
their ocular complaints [58]. Patients complain of acute 
onset of blurred vision, shimmering photopsias, dyschro-
matopsia, temporal vision loss, and paracentral or tem-
poral scotomas [59]. Visual acuity may vary from 20/20 
to 20/400 and a relative afferent pupillary defect may be 
present. Visual field testing may show an enlarged blind 
spot. There will be no anterior chamber inflammation. 
However, a mild vitritis is observed. The lesions are typi-
cally ill-defined and yellowish-white in color. They are 
located at the level of the RPE or outer retina and found 
predominantly in the perimacular area and extend out to 
the mid-peripheral retina. These routinely resolve within 
weeks to months and reoccurrence is rare. Mild pigmen-
tary changes may develop following their resolution. 
Classically, foveal granularity is observed [60].
OCT shows disruption of the ellipsoid zone (Fig.  3). 
Accumulation of hyperreflective material that rests on 
the RPE and extends anteriorly through the interdigita-
tion zone, ellipsoid zone, and outer nuclear layer (ONL) 
Fig. 3 Multiple evanescent white dot syndrome. A 26-year-old woman presented with mildly decreased vision and photopsias. Fluorescein angiog-
raphy revealed early hyperfluorescent lesions in a wreathlike configuration (top left) which persist into the late phase (top right). Optical coherence 
tomography shows disruption of the ellipsoid zone, and accumulation of hyperreflective material that rests on the RPE and extends anteriorly 
through the interdigitation zone, ellipsoid zone, and outer nuclear layer (bottom right)
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can also be seen on OCT [61]. FA exhibits a variable 
number of early hyperfluorescent lesions in a wreath-
like configuration in the mid-retina which persists into 
the late phase of the FA [61]. ICGA shows early and 
mid-phase hypocyanescent dots and/or plaques that are 
greater in number than those evident on FA. FAF demon-
strates areas of hyperautofluorescence in the acute phase 
of the disease. Pinpoint hypoautofluorescence corre-
sponding to the foveal granularity may also be seen [62]. 
A recent study examining wide-field FAF showed that the 
lesions first arise in the posterior pole and spread to the 
periphery during the acute stage; the lesions then fade 
from the periphery in a centripetal manner [63]. ERG 
may demonstrate reduced amplitude of the a-wave. The 
EOG may also be abnormal. However, both the ERG and 
EOG tend to normalize following resolution of the dis-
ease [64].
MEWDS has an overall good prognosis as most 
patients’ vision and visual fields are restored to baseline 
in several weeks to months. However, although rare, 
some patient may have a persistent blind spot enlarge-
ment, photopsias, and dyschromatopsia. No treatment is 
typically needed as most cases resolve spontaneously and 
recurrence is rare [60].
Acute posterior multifocal placoid pigment epitheliopathy
Acute posterior multifocal placoid pigment epitheliopa-
thy (APMPPE) is an acute-onset inflammatory disease 
that affects the choriocapillaris, RPE, and outer retina. It 
typically affects young females, often in the second and 
third decades of life [1]. This disease is found equally 
between men and women [50]. Seventy-five percent of 
patients have bilateral presentation with the second eye 
affected within a few days or weeks following the first. 
The etiology is unknown; however, Gass felt APMPPE is 
often preceded by a viral prodrome [65]. Patients com-
plain of bilateral, sudden, painless vision loss.
Ophthalmic examination does not reveal anterior 
inflammation; however, mild to moderate vitreous cell 
may be seen. Numerous, yellow, creamy colored placoid 
lesions are seen in the posterior pole and are not seen 
anterior to the equator. The lesions are often in vari-
ous stages of evolution. A central clearing will be seen 
as they begin to resolve roughly within 2–3 months and 
progressively become hypopigmented. OCT exhibits 
hyperreflectivity of the outer retinal layers in the early 
stages which is thought to reflect swelling of the outer 
retinal cells or presence of inflammatory cell infiltrates 
[66, 67]. As the lesions resolve, hyperreflectivity of the 
outer retinal layers decreases. Disruption of the IS/OS 
junction and outer retina, and RPE atrophy can per-
sist [68–71]. FA reveals lesions that characteristically 
demonstrate early hypofluorescence that subsequently 
hyperfluorescence in the late venous phase. The lesions 
seen on FAF are hypoautofluorescent and appear later 
and are less numerous than APMPPE lesions seen clini-
cally. In the acute phase of disease, ICGA reveals more 
numerous hypocyanescent lesions than those seen on 
ophthalmoscopy. Studies have revealed that in the acute 
phase of disease, a large delay in choroidal filling as well 
as extensive areas of choroidal vessel nonperfusion can 
be seen. Furthermore, recovery of the choroidal blood 
flow is evident during clinical resolution [72–74]. OCT 
angiography has demonstrated these hypoperfused areas 
corresponding to the changes seen on ICGA [75]. Deut-
man et al. studied EOG and ERG recordings in APMPPE 
patients. ERG findings revealed marginally abnormal val-
ues of the a- and b-wave amplitudes in the acute phase 
of disease. The EOG recordings were also abnormal in 
the acute phase but showed improvement with disease 
resolution [76] which is usually seen within 2–3 months. 
These course is often self-limiting and patients typically 
have a good visual prognosis. However, foveal involve-
ment, older age, unilateral disease, and recurrent disease 
are features that may contribute to poor visual progno-
sis. In these cases systemic steroids have been reported as 
beneficial but further studies are needed to determine if 
there is true efficacy [59].
Serpiginous choroiditis
Serpiginous choroiditis (SC) is a rare condition that 
affects men slightly more than women in their second 
to seventh decades of life [50, 59, 77–79]. It typically is a 
bilateral disease that is chronic and progressive in nature. 
The RPE, choriocapillaris, and choroid are involved 
[80–83].
Although SC usually has bilateral involvement, patients 
typically present with unilateral decreased central vision, 
metamorphopsia, or scotoma. Anterior segment inflam-
mation is usually mild, and the vitreous may be clear or 
show minimal inflammation. Ophthalmoscopy reveals 
lesions originating in the peripapillary region or macula 
in active disease that appear as areas of grayish or creamy 
yellow sub-retinal infiltrates. These lesions progress in 
an irregular serpentine or helicoid fashion centrifugally 
(Fig.  4). Overlying retina edema is also present. Differ-
ent stages of healing are seen between the lesions as they 
resolve, typically around 8-weeks. This resolution leaves 
areas of atrophy involving both the choriocapillaris and 
RPE. Multiple recurrences are common and new lesions 
are classically found at the edge of previous atrophic 
scars. Macular involvement is associated with worse vis-
ual prognosis and higher risk of secondary CNV.
Active lesions on OCT show hyper-reflectivity and 
thickening of the outer retina. There is also increased 
reflectance of the choroid which has been referred to as 
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Fig. 4 Serpiginous choroiditis. A 68-year-old woman presented with chronic visual field defects in both eyes. Lesions deep to the retina were noted 
bilaterally emanating from the optic disc (top row). Fundus autofluorescence revealed central hypoautofluorescence with rims of hyperautofluo-
rescence (second row). Fluorescein angiography showed central patches of hypofluorescence with hyperfluorescent staining over time (third row). 
Central spectral-domain optical coherence tomography revealed a normal fovea, but there was disruption of the ellipsoid zone, external limiting 
membrane, and retinal pigment epithelium, nasally (bottom rows). The yellow arrow corresponds to the same area illustrated in all images
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the ‘waterfall’ effect. The photoreceptor inner and outer 
segment (IS/OS) junction in both active and inactive 
lesions will be disrupted [84]. FA of the active lesions 
show early hypofluorescence and late hyperfluorescence 
of the border in a typical geographic pattern. Old lesions 
show window defects, and late staining. ICGA can be 
divided into four stages. The first reveals hypocyanescent 
lesions in the subclinical or choroidal stage. The second, 
hypocyanescent lesions in the active phase. Third, hyper-
cyanescence in the healing and sub-healing stage and 
the fourth is hypocyanescent lesions with clearly defined 
margins in the inactive phase [50, 85]. FAF shows new 
hyperautofluorescent lesions appearing at the edge of 
old lesions which are hypofluorescent [85]. Electrophysi-
ologic studies are usually normal.
Rapid control of the active lesions with periocular and 
systemic corticosteroids are necessary to limit extensive 
scarring and secondary CNV [77, 87]. Long-term ster-
oid-sparing therapy such as cyclosporine, azathioprine, 
cyclophosphamide, interferon alpha-2a, or mycopheno-
late mofetil may be needed to prevent recurrence [78, 
88–91]. It should be noted that tuberculosis can cause a 
serpiginous-like choroidopathy (SLC). SLC is less likely 
to respond to sole treatment with systemic corticoster-
oids or immunosuppressants making Tb testing manda-
tory especially in endemic regions. Differentiating SC 
and SLC based on imaging findings is discussed in the 
infectious section below.
Relentless placoid chorioretinitis
Relentless placoid chorioretinitis (RPC) is a chronic, 
relapsing disease of unknown etiology. Men and women 
are equally affected typically in their second to sixth dec-
ades of life [92]. Patients may complain of blurred vision, 
metamorphopsia, pericentral scotomas, photopsias, and/
or floaters [93]. It was formerly known as ampiginous 
chorioretinitis.
This disease is often confused with APMPPE and SC. 
RPC can appear very similar to APMPPE or macular 
serpiginous initially, and the relentless course beyond 
6  months is often the key to its diagnosis and differen-
tiation from APMPPE. Ophthalmoscopy reveals creamy 
white lesions roughly one-half disc diameters in size at 
the level of the RPE initially in the posterior pole [94]. 
The lesions are often found bilaterally affecting the mid- 
and far periphery first with subsequent involvement of 
the posterior pole and/or macula. The lesions can remain 
active and spread or heal causing pigmented chorioreti-
nal atrophy. The presence of > 50 to hundreds of lesions 
in different stages of activity found anterior and posterior 
to the equator is characteristic of this disease entity [1]. 
Anterior chamber and vitreous cells are typically seen. 
A similar condition is persistent placoid maculopathy, 
which is more in the MEWDS spectrum. RPC can be dis-
tinguished from persistent placoid in that RPC tends to 
occupy the peripheral retina.
If foveal lesions are present in RPC, OCT may reveal 
subfoveal fluid. In addition, a pigment epithelial detach-
ment (PED) with hyperreflectivity of the inner and outer 
retinal layers can also be seen [95]. FA reveals early hypo-
fluorescence and late staining (Fig.  5). Yeh et  al. [86] 
looked at FAF imaging of a patient with RPC which dis-
played widespread hypoautofluorescence involving the 
posterior pole and mid-peripheral retina. Hypocyanes-
cence in the areas corresponding to the clinical lesions 
that persists into the late phases is seen on ICGA [92, 93]. 
ERG and EOG are normal. Treatment involves systemic 
corticosteroids with addition of immunosupressives if 
Fig. 5 Relentless placoid chorioretinitis. Numerous chorioretinal scars of different ages are evident in the fundus photo (left) of this 25 year-old 
patient with relentless placoid chorioretinitis. Similar findings were present in the other eye. Fluorescein angiography (right) demonstrates staining 
of the chorioretinal scars in the late phase with blockage from the older hyperpigmented regions. These lesions were deemed inactive
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warranted. Although this is a chronic disease and relapse 
is common, the long-term visual prognosis is generally 
good.
Birdshot chorioretinopathy
Birdshot chorioretinopathy (BCR) has a slight female 
predominance and is typically found in patients between 
the ages of 40 and 60 [96–98]. The etiology of BCR 
remains unclear, however studies have shown that of 
the patients who have BCR, nearly 90% possess human 
lymphocyte antigen (HLA) A29. This is the highest asso-
ciation of any HLA antigen with a human disease [97]. 
Testing for HLA-A29 in useful in making the diagnosis as 
it has a sensitivity of 96% and specificity of 93% [48, 99].
Patients may initially complain of blurred vision that is 
often out of proportion to the visual acuity loss, floaters, 
photopsia, and later may experience nyctalopia or color 
blindness. Creamy lesions seen on fundus examination 
are typically oval or round in shape, and one-quarter to 
one-half disc diameter in size. They can present asym-
metrically between the eyes and be subtle in appearance. 
The lesions typically cluster around the optic disk, most 
commonly nasal and inferior to the disk, and radiate out 
to the equator (Fig.  6) [100]. Vitreous inflammation is 
seen in nearly every patient. However, inflammation in 
the anterior segment is generally absent. Retinal vascu-
litis manifests as narrowed retinal vessels [59]. CME, and 
disc edema can also be seen [96].
OCT is typically employed to follow CME. Interest-
ingly, a recent study used extramacular EDI-OCT and 
found BCR patients had focal or generalized disruption 
of the photoreceptor IS/OS junction. Many patients 
Fig. 6 Birdshot uveitis. A 58-year-old woman presented with photophobia in both eyes. White, deep, multifocal, choroidal lesions were seen on 
examination, mostly located nasally (top row). Fundus autofluorescence showed that these lesions were hypoautofluorescent (second row). The 
lesions were hyperfluorescent on fluorescein angiography (third row), and corresponded to hypocyanescent spots on indocyanine green (bottom 
row). Spectral-domain optical coherence tomographies of the fovea in both eyes were relatively unremarkable. Enhanced-depth imaging of lesions 
seen on previous imaging (yellow circles) demonstrates focally disrupted outer retinal structures with increased transmission into the choroid. Work-
up revealed HLA-A29 positivity
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exhibited thinning or absence of the Sattler layer, or had 
an appearance of generalized atrophy of the choroid 
[101]. FA reveals optic disc hyperfluorescence, vascular 
leakage, late CME, and prolonged arteriovenous transit 
time [97, 102]. This delayed transit time is a phenom-
enon call “quenching” and is unique to BCR [48]. With 
FAF, hypoautofluorescent areas corresponding to areas 
of chorioretinal atrophy are noted [86]. ICGA is a sensi-
tive diagnostic test and useful at visualizing the birdshot 
lesions as areas of blockage in the early to midphase. 
A recent report showed a series of patients with BCR 
exhibiting lesions on ICGA before the lesions were visible 
on clinical examination or FA [103]. ERG has been shown 
to be abnormal in 88.8% of patients in a study that ana-
lyzed data from 10 published articles (89 patients) [97]. 
Classically delayed 30-Hz implicit time and diminished 
scotopic b-wave amplitudes will be seen [104]. The ERG 
is an important tool for studying progression of disease. 
EOG is typically normal. Visual field examinations are 
important as peripheral constriction, enlarged blind spot, 
central or paracentral scotomas can be present.
Long-term prognosis is guarded as the disease is 
chronic and does not appear to regress. The causes of 
vision loss is multifactorial and includes loss of photore-
ceptors, macular edema, and disc edema leading to optic 
disc atrophy. In the short term, corticosteroids can be 
used. However, due to their side effects, steroid-sparing 
medications like cyclosporine, azathioprine, mycopheno-
late mofetil, methotrexate or biologics should be consid-
ered for long-term management.
Neoplastic
Three distinct forms of intraocular lymphoma exist and 
include primary vitreoretinal (PVRL), primary uveal and 
secondary (metastatic) lymphoma. Primary vitreoretinal 
lymphoma (PVRL) affects the vitreous and RPE. Uveal 
tissue is the primary site of involvement in metastatic and 
uveal lymphoma [105–107]. Most patients present with 
painless, decreased visual acuity or floaters [108, 109].
PVRL is the most common intraocular lymphoma and 
is often associated with central nervous system (CNS) dis-
ease. It is commonly seen in older or immunocompromised 
patients. Most cases are bilateral, but asymmetric in pres-
entation [110, 111]. The presence of clumped vitreous cells 
and multiple irregular yellowish white sub-RPE deposits are 
pathognomonic features [112–115]. Punched-out lesions 
leading to a disciform-like scar, retinal vasculitis, solid RPE 
detachment or exudative retinal detachment can also be 
present. OCT can show pigment epithelial detachments 
and exudates above the RPE [116]. EDI-OCT is particularly 
useful for choroidal lymphoma that has thin tumor infiltra-
tion. It may show a “placid, rippled, or stormy (seasick)” 
appearance depending on the thickness of invasion [117]. 
FA findings can vary and may reveal staining of subretinal 
deposits, RPE window defects, and diffuse RPE granularity 
[106, 118]. FAF will show hyperautofluorescence of the RPE 
over the lymphoma deposits. Retinal deposits overlying the 
RPE are hypoautofluorescent due to blocking. A study by 
Casady et  al. showed that the majority of patients have a 
granular hyperautofluorescence and hypoautofluorescence 
on FAF. All of these patients were also found to have active 
disease at the time of imaging [119].
Primary uveal and secondary (metastatic) lymphoma 
usually present unilaterally [120]. The majority of patients 
have vitreous cell on examination. Anterior cell and flare 
is rare. Characteristically, multiple yellow subretinal infil-
trates will be seen on fundus examination that may result 
in overlying RPE detachments [121]. Creamy thickening 
of the choroid diffusely and RPE clumping may also be 
present. Collections of tumor cells in the sub-RPE can 
be seen on OCT. FA may demonstrate RPE granular-
ity, blockage by RPE pigment clumps or disrupted RPE, 
and late staining [118, 122]. Tumor cell infiltrates may 
be seen as round hypofluorescent lesions [123]. Diffuse 
uveal thickening, subretinal masses, and intravitreal cells 
can be seen on ultrasonography. Typically, ICGA reveals 
hypocyanescent lesions corresponding to the clinically 
observed choroidal infiltrates [120].
Infectious
Some infectious etiologies can be confused for the WDS’s, 
including syphilitic chorioretinitis, ocular tuberculosis 
(TB), and Lyme disease. These infections are treatable 
masquerade syndromes, thus any suspicion in the history 
or exam findings should prompt a laboratory workup.
Syphilitic inflammatory lesions can be seen affect-
ing the outer retina, RPE, and choroid. The lesions in 
the fundus may appear as yellow, placoid, chorioretinal 
lesions in the posterior pole or within the macula (Fig. 7) 
[124]. A faded center and clumping of the adjacent reti-
nal pigment epithelium may be present. OCT may reveal 
areas of loss in the IS/OS junction and external limiting 
membrane [125, 126]. Hypofluorescent areas can be seen 
on FA corresponding to the fundus lesions. Sporadically 
leopard spotting may be seen as hypo- and hyperfluores-
cence in the faded part of the lesions, followed by pro-
gressive hyperfluorescence [127]. ERG may be markedly 
reduced [128].
Ocular tuberculosis (TB) most commonly affects the 
choroid. Choroidal tuberculomas, choroidal tubercles, 
multifocal choroiditis, and serpiginous-like choroiditis can 
be seen [129, 130]. Miliary choroidal tubercles appear as 
small flat, yellow-white lesions with indistinct borders in 
the choroid and can grow into a single mass lesion called 
a tuberculoma (Fig.  8). A study by Salman et  al. studied 
OCT findings in nine patients with choroidal tuberculosis 
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and found areas of localized adhesion between the RPE-
choriocapillaris layer and the overlying neurosensory 
retina. They termed this the “contact sign” [131]. FA of 
choroidal tubercles show hypofluorescent lesions dur-
ing dye transit then become hyperfluorescent in the late 
frames. However, healed tubercles will show transmission 
hyperfluorescence. Choroidal tuberculomas show early 
hyperfluorescence that increases in hyperfluorescence, 
with pooling of dye during the late phase secondary to an 
exudative retinal detachment [132]. FA in serpiginous-
like choroiditis reveals hypofluorescence of the active 
edge initially with late hyperfluorescence of the advancing 
edge [133]. ICGA of choroidal lesions in the acute phase 
will appear hypofluorescent during the initial and transit 
period. However, as the angiogram progresses into the late 
phase, the edges become hyperfluorescent. In contrast, 
active lesions seen in serpiginous-like choroiditis are seen 
as hypofluorescent spots during the early and late phases 
of ICGA. Patients with ocular Lyme disease characteristi-
cally complain of photophobia and severe periodic ocular 
pain [134]. Choroiditis has been reported [134, 135] and 
described as multiple, well circumscribed creamy lesions 
seen deep in the retina with pigmentation and choroidal 
atrophy. FA in one case revealed deep hypofluorescence 
of the creamy lesions that contrasted with the granular 
hyperfluorescence of the lesions seen in the periphery.
Fig. 7 Syphilitic Uveitis. A 55 year-old man presented with new onset panuveitis in the right eye; he was found to be seropositive for syphilis. Color 
fundus photo (top left) and autofluorescence (top right) of the right eye demonstrate the characteristic placoid appearance of the syphilitic lesions. 
Optical coherence tomography (bottom) reveals segmental loss of ellipsoid zone
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Fig. 8 Panuveitis Secondary to Tuberculosis. Color fundus photograph (top left) of a 50 year-old woman with a history of tuberculosis developed 
serpiginous choroidal atrophy in the left  and right eyes. Fluorescein angiography (top right), indocyanine green angiography (bottom left) and fundus 
autofluorescence (bottom right) demonstrate areas of hypofluorescence corresponding to the regions of chorioretinal atrophy
Conclusion
Given their overlapping historical, clinical and imaging 
features, the white dot syndromes and their masqueraders 
represent a difficult diagnostic challenge for many clini-
cians. Distinguishing these entities is important as some of 
these entities such as APMPPE have a self-limited course 
and an excellent visual prognosis while others such as bird-
shot chorioretinopathy have a chronic course and a more 
guarded prognosis. Furthermore, accurate diagnosis can 
ensure appropriate monitoring is initiated. Entities such 
as PIC must be monitored closely to detect development 
of CNV to ensure early vision saving treatment. Correct 
diagnosis can also aid in laboratory testing for associated 
autoimmune conditions or infectious associations. Ongo-
ing research and expanded imaging techniques have made 
it apparent that each syndrome represents a unique entity 
with specific anatomic localization (Table  2). Combining 
imaging modalities including SD-OCT, enhanced depth 
SD-OCT, FA, ICGA, ultrasonography, wide-field imaging, 
autofluorescence, and now OCT angiography can greatly 
help in distinguishing between the various WDS’s.
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